Biweekly cetuximab in combination with capecitabine and oxaliplatin (XELOX) or irinotecan (XELIRI) in the first-line and second-line treatment of patients with RAS wild-type metastatic colorectal cancer

BACKGROUND: Oral capecitabine in combination with intravenous oxaliplatin (XELOX) or irinotecan (XELIRI) are acceptable substitutions to fully intravenous regimens. Biweekly (as opposed to weekly) cetuximab is more convenient when combined with biweekly chemotherapy. Here, we report the tolerability...

Descripción completa

Detalles Bibliográficos
Autores principales: Zekri, Jamal, Baghdadi, Mohammed Abbas, Ibrahim, Refaei Belal, Meliti, Abdelrazak, Sobahy, Turki M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9934971/
https://www.ncbi.nlm.nih.gov/pubmed/36819803
http://dx.doi.org/10.3332/ecancer.2022.1490

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9934971/
https://www.ncbi.nlm.nih.gov/pubmed/36819803
http://dx.doi.org/10.3332/ecancer.2022.1490

Ejemplares similares